Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRNA | Common Stock | Sale | -$1.28M | -10K | -0.39% | $127.69 | 2.53M | Jun 22, 2022 | Direct | F1 |
holding | MRNA | Common Stock | 12.9M | Jun 22, 2022 | By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. | F2 | |||||
holding | MRNA | Common Stock | 3.92K | Jun 22, 2022 | By Flagship Pioneering, Inc. | F3 |
Id | Content |
---|---|
F1 | These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021, as amended on March 11, 2022. |
F2 | 10,801,059 shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and 2,081,760 shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
F3 | 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |